Top Page
Oxford BioMedica
(LSE:OXB)
Oxford BioMedica (OXB) vs. iShares MSCI United Kingdom ETF (EWC)
Oxford BioMedica Business Overview & Revenue Model
Oxford BioMedica Earnings Call Summary
Oxford BioMedica Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 128.80M | 89.54M | 139.99M | 142.80M | 87.73M |
| Gross Profit | 53.02M | 39.73M | 69.18M | 82.64M | 46.07M |
| EBITDA | -14.33M | -148.62M | -10.86M | 33.22M | 3.92M |
| Net Income | -43.19M | -157.49M | -45.16M | 19.01M | -6.25M |
Balance Sheet | |||||
| Total Assets | 231.64M | 252.34M | 460.18M | 237.23M | 183.93M |
| Cash, Cash Equivalents and Short-Term Investments | 60.65M | 103.72M | 141.31M | 109.02M | 46.98M |
| Total Debt | 108.76M | 111.46M | 114.28M | 9.34M | 13.85M |
| Total Liabilities | 171.16M | 174.51M | 223.99M | 49.89M | 71.18M |
| Stockholders Equity | 57.05M | 74.01M | 204.65M | 187.34M | 112.75M |
Cash Flow | |||||
| Free Cash Flow | -58.12M | -38.35M | -28.91M | 15.99M | -10.24M |
| Operating Cash Flow | -50.63M | -28.52M | -12.62M | 25.45M | 3.12M |
| Investing Cash Flow | 5.63M | 2.81M | -56.46M | -9.46M | -10.80M |
| Financing Cash Flow | 2.91M | -12.70M | 98.62M | 46.21M | 38.19M |
Oxford BioMedica Technical Analysis
Oxford BioMedica Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | £1.96B | ― | -23.77% | ― | 7.97% | 12.94% | |
61 Neutral | $467.00M | ― | -66.23% | ― | 43.84% | 74.88% | |
61 Neutral | £346.45M | 8.85 | 11.74% | ― | 38.80% | ― | |
53 Neutral | £218.84M | ― | -73.02% | ― | ― | ― | |
51 Neutral | $7.30B | 0.27 | -62.71% | 2.44% | 15.02% | 0.60% | |
46 Neutral | £101.18M | ― | 167.16% | ― | -100.00% | -23.91% | |
39 Underperform | £150.20M | ― | -95.28% | ― | 84.39% | -41.02% |
Oxford BioMedica Corporate Events
Oxford Biomedica announced that its total issued share capital consists of 106,199,712 ordinary shares, with no shares held in treasury. This figure is crucial for shareholders to determine their interest in the company under the FCA’s rules, impacting how they manage their investments and disclosures.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica has secured a new four-year loan facility of up to $125 million from Oaktree Capital Management to support its global CDMO operations and growth strategy. This financial move will refinance an existing $50 million loan and provide flexibility for future business needs, reinforcing OXB’s position in the cell and gene therapy industry and demonstrating Oaktree’s confidence in the company’s strategic objectives and market leadership.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford BioMedica PLC has reported a strong start to the fiscal year 2025, with revenues for the first half reaching £70-73 million, marking a 38%-44% increase compared to the same period in 2024. The company has secured £149 million in new orders during the first half of 2025, more than doubling the previous year’s figures, and has reiterated its full-year revenue guidance of £160-170 million. The company’s multi-vector, multi-site strategy is progressing well, with increased demand for its services and a strong order book providing confidence in future growth. OXB is expanding its manufacturing and development capacity to meet growing demand, particularly in late-stage lentiviral programs, and is enhancing its global operations to support clients across various geographies and development stages.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica announced the appointment of Mr. Colin Bond as an Independent Non-Executive Director of OneSource Specialty Pharma Limited, pending shareholder approval. This appointment reflects OXB’s strategic efforts to strengthen its leadership and expand its influence in the global cell and gene therapy market.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £5.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford BioMedica has completed the acquisition of the remaining 10% stake in its US subsidiary from Q32 Bio, Inc., achieving full ownership. This move aligns with OXB’s global strategy and strengthens its position in the viral vector manufacturing market, particularly in the US. The acquisition supports the company’s long-term growth by meeting the increasing demand for high-quality vector manufacturing, a crucial component of the expanding cell and gene therapy market. The fully integrated US facility in Bedford, MA, enhances OXB’s global network, offering lentiviral and AAV vector capabilities and supporting new programs in the US.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica PLC announced that Dr. Heather Preston, a Non-Executive Director, purchased 11,389 ordinary shares of the company at £3.24 each on the London Stock Exchange. This transaction, compliant with EU Market Abuse Regulation, increases her total shareholding to 29,687 shares, representing 0.028% of the company. This purchase reflects confidence in the company’s strategic direction and may positively influence stakeholder perception.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica announced the successful passing of all resolutions at its Annual General Meeting, including board changes with Stuart Henderson stepping down and Colin Bond and Peter Soelkner assuming new roles. These changes are expected to impact the company’s governance and strategic direction, reinforcing its position in the cell and gene therapy industry.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica, a leader in cell and gene therapy manufacturing, reports strong commercial momentum and operational progress in 2025, maintaining its financial guidance and outlook set earlier this year. The company continues to support clients across development stages, with no new material information disclosed at the AGM, reinforcing confidence in its near and medium-term targets.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford BioMedica PLC has announced a change in its voting rights structure following an acquisition by Briarwood Chase Management LLC, a New York-based entity. The acquisition has resulted in Briarwood Chase Management LLC holding 13.0563% of the voting rights in Oxford BioMedica, an increase from the previous 12.019%. This change in voting rights could potentially influence the company’s strategic decisions and impact its market positioning, as stakeholders may see shifts in governance and operational focus.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica has applied for a block listing of 250,000 ordinary shares on the London Stock Exchange, as part of its Long Term Incentive Plan. This move is expected to enhance the company’s market presence and provide additional capital for its operations, reinforcing its position as a leader in the cell and gene therapy industry.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £5.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica has launched its Innovation and Technology Excellence Board (ITEB) to enhance its position as a leader in cell and gene therapy. The board, comprising experts in the field, will guide the company on technology priorities and innovation opportunities, aiming to improve scientific capabilities and maintain OXB’s market-leading status. This initiative is expected to strengthen OXB’s value proposition to clients and support the development of transformative therapies.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica PLC announced that its issued share capital as of May 31, 2025, consists of 106,093,858 ordinary shares, with no shares held in treasury. This figure represents the total number of voting rights in the company, which shareholders can use to determine their notification requirements under FCA rules.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Oxford Biomedica has announced the grant of nil-cost share options under its 2024 Long Term Incentive Plan and Deferred Bonus Plan. These grants, aimed at aligning with the company’s growth strategy, focus on key metrics such as EBITDA margin and revenue growth, which are crucial for stakeholders and reflect the company’s commitment to incentivizing its leadership team.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.